<DOC>
	<DOCNO>NCT00898924</DOCNO>
	<brief_summary>RATIONALE : Collecting store sample tissue patient cancer study laboratory may help doctor learn change may occur DNA identify biomarkers related cancer . PURPOSE : This laboratory study look epidermal growth factor receptor mutation k-ras oncogene mutation patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Epidermal Growth Factor Receptor K-ras Mutations Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine frequency epidermal growth factor receptor ( EGFR ) K-ras mutation patient stage III non-small cell lung cancer ( NSCLC ) treat CALGB 30106 . - Correlate presence absence EGFR and/or K-ras mutation radiographic response treatment patient . OUTLINE : Tissue sample analyze epidermal growth factor receptor K-ras mutation .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : 1 . Eligible patient histologic documentation un treat stage III NSCLC . 2 . Radiation oncologist confirmation require radiation could give per protocol . 3 . Eastern Cooperative Group Criteria Performance Status 0 2 4 . Tumor specimen paraffin block unstained slide standard initial laboratory test 5 . Signed institutional review boardapproved , protocolspecific form consent accordance federal institutional guideline Exclusion criterion : 1 . Patients scalene , supraclavicular , contralateral hilar lymph node involvement , direct invasion vertebral body pleural effusion ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>